Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.

The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant

The placebo is administered twice, 2 months apart